| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1586/ERN.10.38 |
| P698 | PubMed publication ID | 20420497 |
| P50 | author | Mathias Buttmann | Q53308665 |
| P2093 | author name string | Mathias Buttmann | |
| P2860 | cites work | Melanoma complicating treatment with natalizumab for multiple sclerosis | Q46767631 |
| Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism | Q46845177 | ||
| Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis | Q47274470 | ||
| Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. | Q47763052 | ||
| The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group | Q48135012 | ||
| Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. | Q48427388 | ||
| Primary central nervous system lymphoma in a patient treated with natalizumab | Q48444344 | ||
| Progressive multifocal leukoencephalopathy after natalizumab monotherapy | Q48463331 | ||
| Treatment of progressive multifocal leukoencephalopathy associated with natalizumab | Q48463340 | ||
| A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses | Q48602930 | ||
| Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology | Q48718638 | ||
| Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study | Q48828618 | ||
| The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. | Q50766232 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Melanoma following treatment with alemtuzumab for multiple sclerosis. | Q51817061 | ||
| B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. | Q51890331 | ||
| Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. | Q51987968 | ||
| Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis. | Q52905644 | ||
| Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. | Q53654834 | ||
| Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. | Q54146573 | ||
| Daclizumab in treatment of multiple sclerosis patients | Q57083584 | ||
| BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma | Q24646563 | ||
| GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study | Q24647794 | ||
| Ustekinumab | Q28240342 | ||
| Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors | Q28244625 | ||
| Ocrelizumab: a step forward in the evolution of B-cell therapy | Q28245986 | ||
| Progressive multifocal leukoencephalopathy in a patient treated with natalizumab | Q28255536 | ||
| Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis | Q28255548 | ||
| Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies | Q28256960 | ||
| Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study | Q28257337 | ||
| B-cell depletion with rituximab in relapsing-remitting multiple sclerosis | Q28268626 | ||
| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis | Q28270998 | ||
| Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis | Q28271008 | ||
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) | Q28280453 | ||
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) | Q28280465 | ||
| Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial | Q28285743 | ||
| Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study | Q28290823 | ||
| The human polyomavirus, JCV, uses serotonin receptors to infect cells | Q28294207 | ||
| IL-23 drives a pathogenic T cell population that induces autoimmune inflammation | Q29547525 | ||
| Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain | Q29614225 | ||
| Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis | Q29620481 | ||
| Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. | Q30448599 | ||
| Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). | Q30787775 | ||
| Alemtuzumab vs. interferon beta-1a in early multiple sclerosis | Q33381736 | ||
| Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project | Q33383576 | ||
| Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. | Q33502327 | ||
| Unmasking of PML by HAART: unusual clinical features and the role of IRIS | Q33672408 | ||
| Th17 cells: effector T cells with inflammatory properties | Q33732092 | ||
| A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis | Q34093899 | ||
| Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases | Q34172921 | ||
| Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis | Q34311395 | ||
| New insights into progressive multifocal leukoencephalopathy | Q34323449 | ||
| A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. | Q34328813 | ||
| Revised diagnostic criteria for neuromyelitis optica | Q34529345 | ||
| The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. | Q34540035 | ||
| Mitoxantrone: benefits and risks in multiple sclerosis patients | Q37625917 | ||
| Immune reconstitution syndrome and the thyroid | Q37639649 | ||
| Changing incidence of central nervous system diseases in the EuroSIDA cohort | Q38479888 | ||
| Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. | Q39770767 | ||
| Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope | Q39772241 | ||
| Identification and characterization of mefloquine efficacy against JC virus in vitro | Q39877627 | ||
| Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. | Q40476622 | ||
| Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas | Q40550215 | ||
| Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts | Q40695150 | ||
| The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line | Q41013438 | ||
| The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%? | Q42573163 | ||
| Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis | Q42645688 | ||
| BAFF mediates survival of peripheral immature B lymphocytes | Q42944182 | ||
| Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management | Q44412715 | ||
| Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta | Q44597307 | ||
| Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases | Q44893878 | ||
| Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial | Q45119459 | ||
| Natalizumab: bound to rebound? | Q45234957 | ||
| A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses | Q45302161 | ||
| JC virus detection in bodily fluids: clues to transmission | Q45415900 | ||
| Progressive multifocal leukoencephalopathy as a complication of hepatitis C virus treatment in an HIV-negative patient | Q45436293 | ||
| Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease | Q45500943 | ||
| The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. | Q45740735 | ||
| Glatiramer acetate treatment in PPMS: why males appear to respond favorably. | Q46019622 | ||
| Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. | Q46019776 | ||
| Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study | Q46276281 | ||
| Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis | Q46406633 | ||
| An open label study of the effects of rituximab in neuromyelitis optica | Q46482210 | ||
| Oral fingolimod (FTY720) for relapsing multiple sclerosis | Q34565985 | ||
| Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody | Q34585485 | ||
| First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial | Q34590091 | ||
| Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. | Q34596171 | ||
| Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring | Q34619064 | ||
| Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results | Q34665233 | ||
| Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. | Q34788240 | ||
| Asymptomatic reactivation of JC virus in patients treated with natalizumab | Q34801034 | ||
| Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients | Q34823634 | ||
| Determinants of survival in progressive multifocal leukoencephalopathy | Q35012056 | ||
| Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand | Q35957193 | ||
| The BAFF/APRIL system: an important player in systemic rheumatic diseases | Q35963682 | ||
| Cladribine for multiple sclerosis: review and current status | Q36307847 | ||
| IL-12 unmasks latent autoimmune disease in resistant mice | Q36367147 | ||
| An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. | Q36400329 | ||
| Autoimmunity during lymphopenia: a two-hit model | Q36502790 | ||
| Interferon beta1-a and selective anti-5HT(2a) receptor antagonists inhibit infection of human glial cells by JC virus | Q36597132 | ||
| Therapy Insight: CNS manifestations of HIV-associated immune reconstitution inflammatory syndrome | Q36600970 | ||
| Autoimmunity following haematopoietic stem-cell transplantation | Q36797795 | ||
| Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab | Q36986787 | ||
| Treating multiple sclerosis with monoclonal antibodies | Q37111904 | ||
| Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. | Q37159538 | ||
| Advances in the pathogenesis of Goodpasture's disease: from epitopes to autoantibodies to effector T cells. | Q37172655 | ||
| Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy | Q37180592 | ||
| Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? | Q37242800 | ||
| Interleukin 21 as a target of intervention in autoimmune disease | Q37331107 | ||
| Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. | Q37343849 | ||
| Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? | Q37409478 | ||
| Cracking the BAFF code. | Q37517172 | ||
| Ustekinumab: a new option in psoriasis therapy | Q37523846 | ||
| Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project | Q37568787 | ||
| B cell receptor and BAFF receptor signaling regulation of B cell homeostasis | Q37591049 | ||
| Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica | Q37598316 | ||
| P433 | issue | 5 | |
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| multiple sclerosis | Q8277 | ||
| P304 | page(s) | 791-809 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders | Q15760319 |
| P1476 | title | Treating multiple sclerosis with monoclonal antibodies: a 2010 update | |
| P478 | volume | 10 |
| Q36960355 | A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). |
| Q39134948 | Anti-MS4a4B treatment abrogates MS4a4B-mediated protection in T cells and ameliorates experimental autoimmune encephalomyelitis |
| Q41820142 | CD98 is a potential target for ablating B cell clonal expansion and autoantibody in multiple sclerosis |
| Q28533957 | Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis |
| Q48224174 | Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry |
| Q52143402 | Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability. |
| Q33412834 | Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role |
| Q34624835 | Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis |
| Q37997089 | Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis |
| Q30371412 | MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome |
| Q38224993 | MS4A Cluster in Alzheimer's Disease |
| Q37800214 | Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis |
| Q38092121 | Monoclonal antibodies in neuroinflammatory diseases |
| Q37855722 | Multiple sclerosis therapeutic pipeline: opportunities and challenges |
| Q28484467 | Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis |
| Q37892641 | Novel treatment for immune neuropathies on the horizon |
| Q31139925 | Progressive multiple sclerosis: from pathogenic mechanisms to treatment. |
| Q38690022 | Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. |
| Q34330211 | Treating multiple sclerosis with monoclonal antibodies: a 2013 update |
| Q90531435 | Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies |
Search more.